Bristol Myers Squibb is facing a bit of an identity crisis. CEO Chris Boerner is nearly two and a half years into his tenure, with

Pfizer’s positive Phase 3 data in multiple myeloma: The company’s Elrexfio produced a “statistically significant and clinically meaningful improvement” in progression-free survival in patients with

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

AstraZeneca and the UK government are back in each other’s good graces. AstraZeneca on Wednesday said it is lifting its UK investment pause, with a

Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry’s vigorous spring shopping spree. The Italian pharma will